A Leading Preclinical CRO
A Leading Preclinical CRO
We support drug and product preclinical development with trusted GLP and non-GLP scientific services and rodent/non-rodent models.
Bridging innovation and preclinical development to advance healthier products.
Our missions
We advance safety and efficacy steps with cutting-edge preclinical services and models to make the development of pharmaceuticals, chemicals, food, and beyond, a success.
Our missions
Our experts advise you on an efficient testing strategy, aligning with regulatory guidelines — or thinking beyond them— to streamline your path to success.
Our missions
Innovation is our promise. Through collaboration and expertise, we empower clients to pioneer safer, smarter solutions, pushing the boundaries of what’s possible in healthand safetyscience.
Our expertise by
Cardiology
Our expertise by
of reports delivered on-time or before deadlines
studies performed each year
First ERBC site established in Italy, then the second one in France in 1973.
m² of state-of-the art laboratories including BSL1, BSL2 and BSL3.
21 March 25
10 March 25
10 March 25
28 February 25
ERBC, a leading preclinical Contract Research Organization (CRO), provides a comprehensive range of preclinical services, including discovery, toxicology, safety pharmacology, pharmacokinetics, bioanalytics, and translational research together with innovated models such as avian-PDX and Non-Human Primates (NHP). These services are tailored to support the pharmaceutical, biotechnology, chemical, agro-chemical, cosmetic and medical device industries.
Our studies are run at Good Laboratory Practice (GLP) and Good Clinical Practices (GCP) facilities to ensure regulatory compliance and high-quality results.
Engaging with ERBC begins with a consultation with our alliance management directors to understand your specific needs, followed by a tailored proposal outlining study design, timelines, and costs.
Engaging with ERBC begins with a consultation with our alliance management directors to understand your specific needs, followed by a tailored proposal outlining study design, timelines, and costs. Yes, our expertise includes preparing comprehensive regulatory packages, such as SEND-compliant datasets, to support IND and NDA submissions.
We offer end-to-end support, from early-stage discovery through to clinical trial material manufacturing, ensuring seamless progression and adherence to timelines.
